NHS Wales

• 

NICE approves pembrolizumab plus lenvatinib combination for advanced kidney cancer

By Sharon Deveson Kell|2022-11-30T15:29:22+00:0030 Nov 2022|Drug treatments|

The National Institute for Health and Care Excellence (NICE) has [...]

Read More

Comments Off on NICE approves pembrolizumab plus lenvatinib combination for advanced kidney cancer

• 

Health and Care Bill now an Act of Parliament

By Sharon Deveson Kell|2022-06-08T13:25:52+00:007 Jun 2022|Cancer news, Patient advocacy|

The Health and Care Bill received Royal Assent in April following the completion of [...]

Read More

Comments Off on Health and Care Bill now an Act of Parliament

• 

NHS Cancer Programme

By Sharon Kell|2019-12-17T15:41:44+00:0017 Dec 2019|Cancer news|

The NHS Cancer Programme has published its first quarterly update [...]

Read More

Comments Off on NHS Cancer Programme

• 

New first-line treatment option for advanced kidney cancer available on the NHS

By Sharon Kell|2018-02-12T10:48:16+00:0012 Feb 2018|Drug treatments|

Today, the National Institute for Health and Care Excellence (NICE) have recommended tivozanib (Fotivda) [...]

Read More

Comments Off on New first-line treatment option for advanced kidney cancer available on the NHS

Lenvatinib/everolimus combination approved by NICE for use in NHS England and Wales for advanced kidney cancer

By Sharon Kell|2017-12-08T09:36:50+00:008 Dec 2017|Drug treatments|

Fantastic news for people with advanced kidney cancer: the lenvatinib [...]

Read More

Comments Off on Lenvatinib/everolimus combination approved by NICE for use in NHS England and Wales for advanced kidney cancer

• 

Call to transform cancer services to improve survival rates in Wales

By Sharon Kell|2017-08-09T07:43:21+00:009 Aug 2017|Cancer news|

The following article by the BBC reported that 300 more [...]

Read More

Comments Off on Call to transform cancer services to improve survival rates in Wales